Ioannis Hatzaras

Ioannis Hatzaras

Auto-generated profile, based on publicly available information

Ioannis Hatzaras

Department of Surgery, New York University School of Medicine, New York, NY

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

29 October 2015 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
TTThuy B. Tran
Thuy B. Tran
IHIoannis Hatzaras
Ioannis Hatzaras
DWDavid J. Worhunsky
David J. Worhunsky
GVGerardo A. Vitiello
Gerardo A. Vitiello
MSMalcolm Hart Squires
Malcolm Hart Squires
GPGeorge Poultsides
George Poultsides

29 September 2017 in Journal of Gastrointestinal Surgery
Verified
Journal Article
Closed access
PDF file
GKGeorgios Karagkounis
Georgios Karagkounis
MSMalcolm Hart Squires
Malcolm Hart Squires
MMMarcovalerio Melis
Marcovalerio Melis
GPGeorge A. Poultsides
George A. Poultsides
DWDavid Worhunsky
David Worhunsky
IHIoannis Hatzaras
Ioannis Hatzaras

1 April 2016 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
AWAnnie Wang
Annie Wang
MSMalcolm Squires
Malcolm Squires
MMMarcovalerio Melis
Marcovalerio Melis
GPGeorge Poultsides
George Poultsides
JNJeffrey Norton
Jeffrey Norton
IHIoannis Hatzaras
Ioannis Hatzaras
Gastric cancer constitutes a major public health problem. This study sought to evaluate the relevance of race in gastric cancer and its prognostic effect in the overall outcomes of patients with gastric adenocarcinoma. Patients who underwent curative intent resection of gastric adenocarcinoma in 8 institutions of the US Gastric Cancer Collaborative were included, from 2000 to 2012. Nonparametric descriptive statistics were used to evaluate characteristics of standard demographic data. Multivariate Cox proportional hazards regression was used to identify factors associated with recurrence-free survival and overall survival. There were 1,077 patients included in the study, the majority of whom were of Caucasian race (n = 698, 68%), followed by African-American (n = 164, 15%), Asian (n = 132, 12%), Hispanic (n = 34, 3.2%), and other (n = 49, 4.5%). Clinicopathologic data were similarly distributed among the 5 groups. Mean follow-up was 27.1 months. By multivariate, stage-specific analysis, Asian race was a significant predictor of recurrence (all stages hazard ratio [HR] 0.45 95% CI [0.23, 0.97], p = 0.041) and of overall survival (all stages HR 0.35 95% CI [0.18, 0.68], p = 0.002). Recurrence-free survival was significantly increased in the Asian population compared with the non-Asian population (25th percentile: 38.6 vs 17.7 months, p = 0.0096), as was overall median survival (141 vs 38.8 months, p < 0.001). Patients of Asian race undergoing curative gastrectomy for gastric adenocarcinoma appear to have a better prognosis stage for stage. Further studies are required to elucidate the underlying etiology of this phenomenon.

1 February 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TTThuy Tran
Thuy Tran
CECecilia Grace Ethun
Cecilia Grace Ethun
Tim PawlikTim Pawlik
Tim Pawlik
SBStefan Büttner
Stefan Büttner
KIKamran Idrees
Kamran Idrees
GPGeorge Poultsides
George Poultsides
356 Background: Beyond the most common adenocarcinoma type, several gallbladder cancer (GBC) histologies have been described as being associated with more favorable (papillary) or less favorable outcome (adenosquamous, mucinous, signet ring). We sought to examine the added value of histologic type and grade on the existing AJCC staging system for resected GBC. Methods: Patients who underwent resection of GBC from 1988-2013 were identified using the Surveillance Epidemiology End Results (SEER) registry. A prognostic score was created by assigning points for T stage, N stage, grade and histology based on the regression coefficient in multivariate analysis. The score was externally validated using the US Extrahepatic Biliary Malignancy Consortium (USEBMC) database (2000-2015) and compared with the AJCC staging system. Results: Of 7,915 patients identified in SEER, 83% had adenocarcinoma, 7% papillary, 4% adenosquamous, 4% mucinous, and 2% signet ring. In the USEBMC database, the frequencies of the respective histologies were 86, 9, 2, 1 and 2%. Median survival per histologic type, for SEER and USEBMC respectively, were 45 and 110 mos for papillary, 16 and 24 mos for adenocarcinoma, 14 and 12mos for mucinous, 8 and 4mos for adenosquamous, and 9 and 15mos for signet ring (P between histologies < 0.001 for both cohorts). On multivariate analysis, T stage, N stage, grade and histology were independent predictors of survival. The developed prognostic score, based on points for each of these 4 variables, showed excellent discriminatory ability both in the SEER and USEBMC cohorts. The AUC for the prognostic score was significantly improved compared with the AJCC system (0.69 vs. 0.64,both P < 0.001 using SEER, and 0.76 vs. 0.66,both P < 0.001 using USEBMC). Conclusions: The incorporation of histology and grade into the TNM system allows for a simple and accurate tool to determine prognosis following resection of GBC. [Table: see text]

1 February 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
TTThuy Tran
Thuy Tran
CECecilia Grace Ethun
Cecilia Grace Ethun
Tim PawlikTim Pawlik
Tim Pawlik
SBStefan Büttner
Stefan Büttner
KIKamran Idrees
Kamran Idrees
GPGeorge Poultsides
George Poultsides
336 Background: The prognosis of patients with gallbladder cancer (GBC) who present with jaundice has historically been considered dismal, however recent Eastern literature has demonstrated that surgical resection can be associated with long-term survival. The objective of this study was to utilize a contemporary, Western, multi-institutional dataset to examine the prognostic significance of preoperative jaundice on short- and long-term outcomes after GBC resection. Methods: Patients with GBC managed surgically from 2000 to 2015 in 10 academic institutions participating in the U.S. Extrahepatic Biliary Malignancy Consortium were stratified based on the presence of preoperative jaundice (bilirubin > 3 mg/ml or requiring preoperative biliary drainage). Postoperative morbidity, mortality, and overall survival were compared. Results: Of 449 patients with GBC evaluated for resection, 301 (67%) eventually underwent curative-intent resection. Resectability for cure was much lower in patients with preoperative jaundice (48% vs. 79%, p < 0.001). Of 273 patients who underwent curative-intent resection and had available preoperative bilirubin levels, 53 (19%) had preoperative jaundice and were noted to have tumors of T3/4 stage (63% vs 42%, P = 0.008), with lymph node metastasis (63% vs. 41%; p = 0.014), lymphovascular invasion (68% vs 39%; p = 0.003), and R1 margins (37 vs. 9%; p < 0.001). Patients with jaundice more commonly required CBD (55% vs 32%, P = 0.004), major liver (25% vs. 7%; p < 0.001) and portal vein resection (8% vs. 0.5%; p = 0.006), as well as intraoperative blood transfusion (29 % vs. 11%; p = 0.002). Overall morbidity (57% vs. 38%; p = 0.031) and in-hospital mortality (7.5% vs. 1.4%; p = 0.029) rates were higher in patients with jaundice. Overall survival after curative-intent resection was worse in patients with jaundice (median 12 vs 33 months; p < 0.001). Conclusions: Half of GBC patients presenting with jaundice are not resectable for cure and when they are, their 5-year survival is 12%. These patients should not be excluded from multidisciplinary treatment strategies that include surgery, however expectations should be clearly set and selection should be cautious.